Enfusion, Inc.

    Enfusion, Inc.

    NNYSE:ENFN
    10.76
    USD
    -0.04
    (-0.37%)
    335.81P/E
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    0.92
    1.24
    1.34
    1.76
    1.98
    - -
    2.19
    Basic EPS, GAAP
    0.2
    0.06
    -1.9
    -0.09
    0.07
    - -
    0.03
    Free Cash Flow per Basic Share
    0.12
    -0.05
    -0.08
    0.12
    0.24
    - -
    0.34
    Dividend per Share
    0.17
    0.07
    0.04
    - -
    - -
    - -
    - -
    Book Value per Share
    -1.84
    -3.64
    -2.06
    -2.09
    -1.96
    - -
    -1.85
    Tangible Book Value per Share
    -1.84
    -3.65
    1.17
    1.21
    0.88
    - -
    1.08
    Basic Weighted Avg Shares
    64
    64
    83
    85
    88
    - -
    92
    Sales/Revenue/Turnover
    59
    80
    112
    150
    175
    202
    202
    Operating Margin (%)
    23.5
    7.63
    -246.99
    -7.96
    6.85
    3.05
    3.05
    Depreciation Expense
    1
    2
    4
    6
    10
    12
    12
    Net Income, GAAP
    13
    4
    -158
    -8
    6
    3
    3
    Effective Tax Rate (%)
    3.7
    9.64
    - -
    - -
    19.43
    47.02
    47.02
    Profit Margin (%)
    21.44
    5.1
    -141.73
    -5.09
    3.45
    1.4
    1.4
    Working Capital
    8
    18
    82
    79
    50
    66
    66
    LT Debt
    27
    96
    - -
    3
    11
    14
    14
    Total Equity
    -118
    -234
    97
    103
    77
    100
    100
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    9.45
    3.05
    3.05
    Return on Capital (%)
    - -
    -4.95
    - -
    - -
    -2.1
    -1.35
    -1.35
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    ST Debt
    5
    6
    6
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    13
    15
    14
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    92
    93
    95
    Market Capitalization
    763
    866
    948

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    Total Current Assets
    74
    85
    94
    Cash, Cash Equivalents & STI
    34
    48
    54
    Accounts Receivable, Net
    34
    32
    32
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    18
    24
    27
    Payables & Accruals
    4
    6
    7
    ST Debt
    5
    6
    6
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -6.81%
    28.47%
    Free Cash Flow
    - -
    -31.69%
    46.58%
    Net Income, GAAP
    - -
    -878.68%
    -53.15%
    Sales/Revenue/Turnover
    - -
    28.28%
    15.51%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    34
    37
    39
    41
    150
    2023
    41
    43
    44
    46
    175
    2024
    48
    49
    51
    53
    202

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.09
    -0.03
    0.02
    - -
    -0.09
    2023
    0.03
    0.01
    0.02
    - -
    0.07
    2024
    -0.01
    0.02
    0.02
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • seekingalpha.com

      Clearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful Growth

    • seekingalpha.com

      Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy

    • businesswire.com

      Clearwater Analytics Finalizes Acquisition of Enfusion

    • businesswire.com

      Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration

    • businesswire.com

      Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration

    • businesswire.com

      ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN

    • zacks.com

      Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates

    • businesswire.com

      Enfusion Announces Fourth Quarter and Full Year 2024 Results

    • businesswire.com

      Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion

    • businesswire.com

      ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders

    • benzinga.com

      Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock

    • accessnewswire.com

      Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

    • accessnewswire.com

      Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Shareholders to Inquire about Securities Investigation

    • accessnewswire.com

      Bronstein, Gewirtz & Grossman, LLC Is Investigating Enfusion, Inc. (ENFN) And Encourages Investors to Connect

    • accessnewswire.com

      Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Stockholders to Inquire about Securities Investigation

    • accessnewswire.com

      Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Enfusion, Inc. (ENFN) and Encourages Investors to Learn More About the Investigation

    • accessnewswire.com

      Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

    • accessnewswire.com

      The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Enfusion, Inc. For Securities Fraud

    • accessnewswire.com

      Enfusion, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm

    • accessnewswire.com

      Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Stockholders to Reach Out